229 related articles for article (PubMed ID: 9353014)
1. Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge.
Rénia L; Ling IT; Marussig M; Miltgen F; Holder AA; Mazier D
Infect Immun; 1997 Nov; 65(11):4419-23. PubMed ID: 9353014
[TBL] [Abstract][Full Text] [Related]
2. Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain.
Goschnick MW; Black CG; Kedzierski L; Holder AA; Coppel RL
Infect Immun; 2004 Oct; 72(10):5840-9. PubMed ID: 15385485
[TBL] [Abstract][Full Text] [Related]
3. Enhanced protection against malaria by a chimeric merozoite surface protein vaccine.
Shi Q; Lynch MM; Romero M; Burns JM
Infect Immun; 2007 Mar; 75(3):1349-58. PubMed ID: 17158895
[TBL] [Abstract][Full Text] [Related]
4. A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice.
Daly TM; Long CA
Infect Immun; 1993 Jun; 61(6):2462-7. PubMed ID: 8363656
[TBL] [Abstract][Full Text] [Related]
5. Comparison of protection induced by immunization with recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii.
Tian JH; Kumar S; Kaslow DC; Miller LH
Infect Immun; 1997 Aug; 65(8):3032-6. PubMed ID: 9234750
[TBL] [Abstract][Full Text] [Related]
6. The combined epidermal growth factor-like modules of Plasmodium yoelii Merozoite Surface Protein-1 are required for a protective immune response to the parasite.
Ling IT; Ogun SA; Holder AA
Parasite Immunol; 1995 Aug; 17(8):425-33. PubMed ID: 7501423
[TBL] [Abstract][Full Text] [Related]
7. Passive immunization with antibodies against three distinct epitopes on Plasmodium yoelii merozoite surface protein 1 suppresses parasitemia.
Spencer Valero LM; Ogun SA; Fleck SL; Ling IT; Scott-Finnigan TJ; Blackman MJ; Holder AA
Infect Immun; 1998 Aug; 66(8):3925-30. PubMed ID: 9673281
[TBL] [Abstract][Full Text] [Related]
8. Protection of mice against Plasmodium yoelii sporozoite challenge with P. yoelii merozoite surface protein 1 DNA vaccines.
Becker SI; Wang R; Hedstrom RC; Aguiar JC; Jones TR; Hoffman SL; Gardner MJ
Infect Immun; 1998 Jul; 66(7):3457-61. PubMed ID: 9632624
[TBL] [Abstract][Full Text] [Related]
9. Plasmodium: immunization with carboxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge.
Rotman HL; Daly TM; Long CA
Exp Parasitol; 1999 Jan; 91(1):78-85. PubMed ID: 9920045
[TBL] [Abstract][Full Text] [Related]
10. Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use.
Ling IT; Ogun SA; Momin P; Richards RL; Garçon N; Cohen J; Ballou WR; Holder AA
Vaccine; 1997 Oct; 15(14):1562-7. PubMed ID: 9330469
[TBL] [Abstract][Full Text] [Related]
11. Members of the merozoite surface protein 7 family with similar expression patterns differ in ability to protect against Plasmodium yoelii malaria.
Mello K; Daly TM; Long CA; Burns JM; Bergman LW
Infect Immun; 2004 Feb; 72(2):1010-8. PubMed ID: 14742548
[TBL] [Abstract][Full Text] [Related]
12. Plasmodium yoelii: the role of the individual epidermal growth factor-like domains of the merozoite surface protein-1 in protection from malaria.
Calvo PA; Daly TM; Long CA
Exp Parasitol; 1996 Jan; 82(1):54-64. PubMed ID: 8617331
[TBL] [Abstract][Full Text] [Related]
13. Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge.
Kedzierski L; Black CG; Coppel RL
Infect Immun; 2000 Oct; 68(10):6034-7. PubMed ID: 10992516
[TBL] [Abstract][Full Text] [Related]
14. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria.
Daly TM; Long CA
J Immunol; 1995 Jul; 155(1):236-43. PubMed ID: 7602100
[TBL] [Abstract][Full Text] [Related]
15. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection.
Narum DL; Ogun SA; Thomas AW; Holder AA
Infect Immun; 2000 May; 68(5):2899-906. PubMed ID: 10768987
[TBL] [Abstract][Full Text] [Related]
16. Protective efficacy against malaria of a combination sporozoite and erythrocytic stage vaccine.
Wang R; Charoenvit Y; Daly TM; Long CA; Corradin G; Hoffman SL
Immunol Lett; 1996 Nov; 53(2-3):83-93. PubMed ID: 9024983
[TBL] [Abstract][Full Text] [Related]
17. Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-gamma-dependent responses induced by vaccination and/or challenge infection.
Petritus PM; Burns JM
J Immunol; 2008 Jan; 180(1):444-53. PubMed ID: 18097046
[TBL] [Abstract][Full Text] [Related]
18. Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection.
Daly TM; Long CA
Infect Immun; 1996 Jul; 64(7):2602-8. PubMed ID: 8698485
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the protective efficacy of yeast-derived and Escherichia coli-derived recombinant merozoite surface protein 4/5 against lethal challenge by Plasmodium yoelii.
Kedzierski L; Black CG; Stowers AW; Goschnick MW; Kaslow DC; Coppel RL
Vaccine; 2001 Sep; 19(32):4661-8. PubMed ID: 11535314
[TBL] [Abstract][Full Text] [Related]
20. CD4(+) T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein.
Charoenvit Y; Majam VF; Corradin G; Sacci JB; Wang R; Doolan DL; Jones TR; Abot E; Patarroyo ME; Guzman F; Hoffman SL
Infect Immun; 1999 Nov; 67(11):5604-14. PubMed ID: 10531206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
